Josep Bassaganya-Riera, NImmune Biopharma

Ex­clu­sive: Af­ter get­ting his drug back, Lan­dos founder as­sem­bles new start­up for the big PhI­II test

By the time Josep Bas­saganya-Ri­era stepped down as found­ing CEO of Lan­dos Bio­phar­ma in 2021, the com­pa­ny had racked up Phase II da­ta for its top au­toim­mune pro­gram, com­plet­ed what he called a pos­i­tive end-of-Phase-II meet­ing with the FDA and plans to launch piv­otal Phase III tri­als.

Since then, though, the new lead­ers at Lan­dos have reshuf­fled their plans for the drug, omi­lan­cor, first an­nounc­ing they will run a Phase IIb ahead of a Phase III and even­tu­al­ly shelv­ing it al­to­geth­er.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters